CD274 and diabetes mellitus: This treatment has shown success to treat cancer (16), yet systemic ICI treatment can also activate other T cells that were suppressed by the PD1–PDL1 interaction, risking autoimmune adverse events including ICI-induced diabetes mellitus (“ICI-DM”) as side effect (17, 18).